STOCKWATCH GPC Biotech leads TecDAX after signing 10.2 bln yen marketing deal (Sharewatch)
STOCKWATCH GPC Biotech leads TecDAX after signing 10.2 bln yen marketing deal (Sharewatch)
FRANKFURT (Thomson Financial) - Shares in GPC Biotech AG were higher in morning trade, bucking a general downward trend among the TecDAX stocks, after the biotech company announced that it signed a 10.2 bln yen deal with Yakult Honsha Co for the exclusive marketing, development and sale of its chemotherapy drug Satraplatin in Japan.